Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) FLT3 Antibodies:
anti-Human FLT3 Antibodies:
anti-Rat (Rattus) FLT3 Antibodies:
Go to our pre-filtered search.
Human Monoclonal FLT3 Primary Antibody for FACS - ABIN2688960
Mackarehtschian, Hardin, Moore, Boast, Goff, Lemischka: Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. in Immunity 1995
Show all 4 Pubmed References
Human Polyclonal FLT3 Primary Antibody for IHC (p), ELISA - ABIN544008
Sitnicka, Buza-Vidas, Larsson, Nygren, Liuba, Jacobsen et al.: Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic ... in Blood 2003
Show all 3 Pubmed References
Human Monoclonal FLT3 Primary Antibody for IHC, ELISA - ABIN1724846
Pereira de Sousa, Berthault, Granato, Dias, Ramond, Kee, Cumano, Vieira: Inhibitors of DNA binding proteins restrict T cell potential by repressing Notch1 expression in Flt3-negative common lymphoid progenitors. in Journal of immunology (Baltimore, Md. : 1950) 2012
Show all 2 Pubmed References
Human Polyclonal FLT3 Primary Antibody for IF - ABIN362818
Sekine, Kataoka, Fukuyama, Adachi, Davydova, Yamamoto, Kobayashi, Fujihashi, Suzuki, Curiel, Shizukuishi, McGhee, Fujihashi: A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. in Journal of immunology (Baltimore, Md. : 1950) 2008
Show all 5 Pubmed References
Human Polyclonal FLT3 Primary Antibody for CyTOF, FACS - ABIN4900037
Armstrong, Kung, Mabon, Silverman, Stam, Den Boer, Pieters, Kersey, Sallan, Fletcher, Golub, Griffin, Korsmeyer: Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. in Cancer cell 2003
Show all 2 Pubmed References
Human Monoclonal FLT3 Primary Antibody for FACS, IP - ABIN1302921
Whartenby, Calabresi, McCadden, Nguyen, Kardian, Wang, Mosse, Pardoll, Small: Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. in Proceedings of the National Academy of Sciences of the United States of America 2005
Show all 5 Pubmed References
Human Monoclonal FLT3 Primary Antibody for FACS, IP - ABIN489931
Kuchenbauer, Kern, Schoch, Kohlmann, Hiddemann, Haferlach, Schnittger: Detailed analysis of FLT3 expression levels in acute myeloid leukemia. in Haematologica 2005
Show all 5 Pubmed References
Mouse (Murine) Monoclonal FLT3 Primary Antibody for FACS - ABIN4272599
Caldarelli, Müller, Paskowski-Rogacz, Herrmann, Bauer, Koch, Heninger, Krastev, Ding, Kasper, Fischer, Brodhun, Böhmer, Buchholz: A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling. in Leukemia 2013
Human Monoclonal FLT3 Primary Antibody for CyTOF, FACS - ABIN4900035
Williams, Li, Nguyen, Brown, Levis, Small: Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. in Blood 2012
Mouse (Murine) Polyclonal FLT3 Primary Antibody for CyTOF, FACS - ABIN4900092
Arora, Stopp, Böhmer, Schons, Godfrey, Masson, Razumovskaya, Rönnstrand, Tänzer, Bauer, Böhmer, Müller: Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. in The Journal of biological chemistry 2011
FLT3 is a biomarker for diagnosis and prognosis of male fertility.
The demonstrated that an E2-2high fraction among common DC progenitors, which are a major source of pDCs and cDCs in the steady state, strictly gave rise to pDCs in the presence of Flt3 (Fms-like tyrosine kinase receptor-3) ligand ex vivo or in the secondary lymphoid organs when transferred in vivo.
Acute myeloid leukemia tumor cell lines expressing the D835Y activation loop mutation of FLT3 failed to form colonies.
Flt3 was heterogeneously expressed by almost all of the hematopoietic stem cell compartments.
SLAP2 acts as a negative regulator of FLT3 signaling and therefore, modulation of SLAP2 expression levels may provide an alternative therapeutic approach for FLT3-ITD positive acute myeloid leukemia
Data show that conditional deletion of Dnmt3a and simultaneous "knock in" of Flt3ITD/+, cooperate to drive leukemia development at a faster rate than Dnmt3a loss alone.
ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia that can be successfully reversed.
Flt3 and cooperating Flt3/Runx1 mutations cause hematopoietic stem cell depletion and myeloid progenitor expansion during adult but not fetal stages of murine development.
Tumor necrosis factor (TNF), a cell-extrinsic potent negative regulator of hematopoietic stem cells (HSCs), was overexpressed in bone marrow niche cells from FLT3 internal tandem duplications (FLT3 ITDs) mice.
the angiogenic factor Egfl7 activates the Flt3/Flt3 ligand pathway and is a key molecular driver enforcing thymus progenitor generation and thereby directly links endothelial cell biology to the production of T cell-based adaptive immunity
the Hoxa9- and Meis1-associated upregulation of Flt3 is a passive event with regard to leukemia development in mice and with limited relevance to the AML pathology.
lineage-specific STAT5 activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype in mice
DOCK2 is a potential therapeutic target for novel AML treatments, as this protein regulates the survival of leukemia cells with elevated FLT3 activity and sensitizes FLT3/ITD leukemic cells to conventional antileukemic agents.
Used a genetic model to determine whether miR-155 influences the development of FLT3-ITD-induced myeloproliferative disease. miR-155 promotes FLT3-ITD-induced myeloid expansion in the bone marrow, spleen, and peripheral blood. Mechanistically, miR-155 increases proliferation of the hematopoietic stem and progenitor cell compartments by reducing the growth-inhibitory effects of the interferon response.
Overexpression of Abl-related gene tyrosine kinase ABL2 in pro-B cell line Ba/F3 cells expressing an oncogenic mutant of FLT3 (FLT3-ITD) resulted in partial inhibition of FLT3-ITD-dependent cell proliferation.
Sorafenib-resistant leukemia cells with a FLT3/ITD mutation are sensitive to glycolytic inhibitors.
FLT3-ITD is capable of inhibiting FLT3-ITD+ cell proliferation through the p21/Pbx1 axis
Data indicate that most Fms-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibitors (TKI) effectively target wild-type FLT3 signaling.
DNMT3A haploinsufficiency results in reversible epigenetic alterations that transform FLT3(ITD)-mutant myeloproliferative neoplasm into AML.
murine Fms-like tyrosine kinase 3 (Flt3) ligand was used to generate conventional dendritic cells (FL-cDCs) and plasmacytoid DCs (FL-pDCs) and further evaluated their immunological responses to bacillus Calmette-Guerin (BCG) infection in vitro.
The five novel heterocyclic compounds (E1QAC1-5) had cytotoxic effects and induced apoptosis in FD-FLT3 cells.
AML patients with FLT3-ITD and DNMT3A R882 double mutations had a very high cumulative recurrence rate and low overall survival, leukocyte-free survival after transplantation
Giant cellulitis-like Sweet syndrome as an initial clinical presentation of acute myeloblastic leukemia with t(6;9)(p23;q34): DEK-CAN and internal duplications of FMS-like tyrosine kinase 3.
In the absence of a concomitant DNA methyltransferase 3A (DNMT3A) mutation, there was no significant difference in overall survival between fms-like tyrosine kinase 3A tandem repeat (FLT3-ITD) positive and FLT3-ITD negative patients.
In this study, the authors show that cytomegalovirus UL7 is a ligand for Fms-like tyrosine kinase 3 receptor (Flt-3R), a well-known critical factor in HPC differentiation. They observed that UL7 directly binds Flt-3R and induces downstream signaling cascades, including phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways.
Study demonstrates that FLT3 internal tandem duplication (FLT3-ITD) can be classified into DNA complete duplication, partial duplication and complete random sequence. High ITD allelic ratio and Allo-SCT treatment under first complete remission are independent prognostic factors. ITD integration sites in the hinge region or beta1-sheet are an unfavorable prognostic factor in adult AML patients with FLT3-ITD mutations.
TKI treatment increased the surface expression through upregulation of FLT3.
Authors have shown that the stability of ETV6/FLT3 is regulated by the Hsp90 chaperone. ETV6/FLT3 fusion protein forms a complex with Hsp90 by coimmunoprecipitation analyses using an Hsp90 antibody.
Multivariate Cox's proportional hazards regression analyses revealed that OCT4 mRNA high expression was an independent predictive factor for shorter EFS and OS in AML patients. Conclusion OCT4 correlates with presence of CK, FLT3-ITD mutation and poorer risk stratification, and it could be served as a convincing biomarker for predicting unfavourable prognosis in AML patients.
Results indicate that DNMT3A mutations alone do not affect the clinical outcomes of AML patients undergoing allogeneic HSCT, but when accompanied by FLT3-ITD mutations, the OS was significantly reduced (5-year OS 0% for DNMT3A R882mut/FLT3-ITDpos patients vs. 62% DNMT3A R882wt/FLT3-ITDneg, p=0.025) and the relapse rate increased.
RIPK3-dependent cell death and inflammasome activation in FLT3-internal-tandem-duplication-expressing leukemia-initiating cells
The results suggested that FLT3 ITD mutations could become an indicator of poor prognosis of APL, and these patients should receive more intensive therapy according to current guidelines.
Low FLT3 expression is associated with Pancreatic ductal adenocarcinoma.
DNMT3A R882 mutation plays an important role in CN-AML patients' prognosis and clinical outcomes in the presence and absence of NPM1 and FLT3 mutations.
the FLT3 inhibitor AC220 inhibited glutamine flux into the antioxidant factor glutathione profoundly due to defective glutamine import.
Mutation in FLT3 gene is associated with Acute Myeloid Leukemia.
Acute myeloid leukemia harboring internal tandem duplication of FMS-like tyrosine kinase 3 (AML(FLT3-ITD)) is associated with poor prognosis.
Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia has been described.
The results of the present study showed that the overexpression of FLT3 is a potential risk factor in leukemia.
In this study, FLT3 and NPM1 mutations were evaluated in adult Iranian patients with de novo cytogenetically normal acute myeloid leukemia and its correlations with clinical and laboratory parameters were also assessed.
This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.
fms-related tyrosine kinase 3
, FL cytokine receptor-like
, FL cytokine receptor
, fetal liver kinase 2
, receptor-type tyrosine-protein kinase FLT3
, tyrosine-protein kinase FLT3
, tyrosine-protein kinase receptor flk-2
, CD135 antigen
, fms-like tyrosine kinase 3
, growth factor receptor tyrosine kinase type III
, stem cell tyrosine kinase 1
, FMS-like tyrosine kinase 3